A microbial cell bank is the starting point for many biological manufacturing and research processes. If its identity, purity or genetic properties change, the consequences may appear much later as inconsistent growth, reduced productivity or unexpected test results. Microbial cell bank characterization provides documented evidence about the bank before it is used and helps compare material across its working life.
geneOmbio Technologies offers contract research services which includes project-specific characterization of bacterial and other microbial banks using sequencing, molecular assays and microbiological methods. The appropriate tests depend on the organism, the bank type, the recombinant construct, the process and the intended use of the results.
What is microbial cell bank characterization?
Microbial cell bank characterization is a set of tests that establishes whether a stored culture is the intended organism, whether unwanted organisms are detectable, whether important genetic features are retained, and whether viable cells can be recovered. For a recombinant strain, the assessment may also cover the expression construct, selectable marker and estimated copy number.
The program may include a master cell bank (MCB), a working cell bank (WCB) and cells collected at or beyond the proposed production culture age, often described as end-of-production cells (EOPC). Each sampling point answers a different question:
| Material | Main characterization question | Possible tests |
| MCB | Is the primary bank correctly identified, sufficiently pure and suitable as the source of future working banks? | Identity, contaminant screening, viability and characterization of relevant construct features |
| WCB | Does the bank derived from the MCB remain suitable for routine use? | Identity, purity, viable count and selected comparisons with the MCB |
| EOPC or cells at the production-age limit | Are relevant properties retained after the defined cultivation history? | Construct sequence or retention, identity and selected phenotypic or productivity measures |
The exact panel and acceptance criteria should be justified for the particular bank. ICH Q5D provides guidance for cell substrates and cell banks used to produce specified biotechnological and biological products; its scope does not extend automatically to every research or industrial microbial bank.
The four questions a characterization program should answer
1. Is this the intended organism or strain?
An identity assessment helps detect a bank mix-up and establishes a reference for later comparison. For bacteria, near-full-length or full-length 16S rRNA gene Sanger sequencing can support species-level identification when the reference sequences and discriminatory power of the marker are adequate. Related species may share highly similar 16S sequences, and 16S alone generally cannot establish the identity of a particular E. coli production strain.
geneOmbio combines 16S sequencing and phylogenetic comparison with other evidence as needed. For E. coli, its published service includes 16S reference-based alignment and API 20E biochemical profiling. When a specific strain or recombinant host must be confirmed, a project may also require distinguishing genetic markers, construct-specific tests or whole-genome sequencing.
For yeast and other fungi, an appropriate fungal marker, such as ITS or LSU, should be selected instead of bacterial 16S rRNA.
2. Is the bank free from detectable contamination?
Purity testing looks for unintended bacteria, yeasts or fungi. A useful culture-based strategy considers the growth properties of the banked organism, the media used, likely contaminants and whether antibiotics or other selective agents could suppress their recovery. Colony appearance on suitable media offers complementary evidence, but a visually uniform culture does not by itself establish the absence of contamination.
geneOmbio’s published cell bank service describes bacterial and fungal impurity testing on multiple media and assessment of possible inhibitory agents. Bacteriophage testing may also be relevant for bacterial production hosts, particularly when phage contamination could disrupt a culture. The assay design and the interpretation of any result should reflect the host and the phages the method can detect.
3. Are important genetic features stable?
In a recombinant bank, plasmid loss, a change in copy number, mutation of a coding sequence or loss of a selectable marker can affect the process. The stability question should be tied to a defined comparison: for example, MCB versus WCB, or early-passage cells versus cells grown to the proposed production-age limit.
Depending on the construct, geneOmbio can assess selectable-marker retention, recombinant-construct retention, restriction fragment patterns, open reading frame (ORF) sequence integrity and copy number by quantitative PCR (qPCR). A qPCR estimate needs an appropriate reference target, controls and interpretation suited to the construct; a plasmid-to-chromosome target ratio should be reported as an estimate under the defined assay conditions, not treated automatically as an exact count for every cell. Restriction analysis can identify major structural differences, while sequencing is needed when the exact nucleotide sequence is the question.
4. Can viable cells be recovered?
Viable-count testing estimates the concentration of cells capable of forming colonies under specified culture conditions. A colony-forming unit (CFU) result supports assessment of recovery from a stored vial and comparison across banks or storage points. It should always be interpreted with the medium, incubation conditions, dilution and sampling method used.
Metabolic assays such as MTT may provide additional information for a suitable organism and validated application. Metabolic signal and CFU measure different properties and should not be presented as interchangeable results.
How sequencing supports microbial cell bank testing
Sequencing can answer two different questions: Which organism is present? and Does a specified genetic sequence match the expected construct? The target and reference must be chosen for the question.
For bacterial identification, DNA is extracted from the recovered culture, the 16S rRNA gene is amplified, and the PCR product is sequenced by Sanger sequencing. Forward and reverse reads are checked for quality and assembled into a consensus sequence. The result is compared with appropriate reference sequences and, when informative, examined in a phylogenetic analysis. Ambiguous chromatograms or closely related matches may trigger further investigation before a final identification is assigned.
For a recombinant strain, primers can be designed around the insert, ORF or relevant vector junctions. Sequence reads are aligned with the approved reference construct to assess the covered regions for substitutions, insertions or deletions. The report should identify the regions actually covered and any gaps; a partial read cannot establish whole-plasmid integrity. When the construct is too large or structurally complex for the planned Sanger coverage, an alternative sequencing strategy may be appropriate.
Choosing the right tests for MCB, WCB and end-of-production cells
The MCB generally receives the broadest initial characterization because it is the source from which working banks are derived. A WCB can then be checked against the MCB using a panel justified by the generation process and the risks of change or contamination. Testing cells at or beyond the production-age limit helps determine whether relevant characteristics persist through the intended cultivation period.
For a recombinant production organism, a practical panel might combine identity testing, culture-based purity tests, a viable count, copy-number estimation, selectable-marker assessment and sequencing of critical construct regions. Phage testing or particular phenotypic markers may be added when the organism and process warrant them. A research bank may call for a different scope from a bank used in a regulated manufacturing process.
Where these services are useful
- Biopharmaceutical development and manufacturing: Characterization of microbial hosts used for recombinant proteins, enzymes, plasmid-related products or other biological materials.
- Quality investigations: Comparison of a bank or later culture with its reference when growth, productivity, identity or purity is questioned.
- Technology transfer and new WCB preparation: Documented comparison of source material and newly expanded banks.
- Research programs: Confirmation that a stored or repeatedly propagated strain still matches the organism and construct required for the study.
The resulting report should connect the sample identity and culture history to the methods, controls, observations, sequence comparisons, conclusions and limitations. For regulated use, the sponsor should align the testing plan and acceptance criteria with its quality and regulatory strategy.
Discuss your microbial cell bank characterization project
To define an appropriate test panel, share the organism and strain, bank type, number of available vials, storage and passage history, construct map or reference sequence where applicable, and the purpose of testing. GeneOmbio can then scope identity, purity, stability and viability studies for an MCB, WCB or end-of-production sample.
Contact geneOmbio about cell bank characterization services.
Frequently asked questions on Cell Back characterization
Is 16S sequencing enough to confirm an E. coli strain?
Usually no. 16S sequencing supports bacterial identification but often cannot distinguish individual E. coli strains. Strain-specific markers, construct analysis or genome-level comparison may be needed, depending on the claim required.
Must the MCB and WCB undergo identical tests?
No universal identical panel applies. The testing strategy should account for how the WCB was prepared, what was established for the MCB, the intended use and the relevant risks.
What does recombinant construct stability testing assess?
It can assess whether a selectable marker or construct is retained and whether tested sequence regions still match the approved reference after defined subculturing or production growth. The exact conclusion depends on the targets, coverage and methods used.
Why consider bacteriophage testing for a bacterial bank?
Some phages can impair bacterial cultures. Testing may be useful when the host, manufacturing history or process risk makes phage contamination a concern; the assay must be suitable for the host and intended detection claim.
Can the characterization panel be customized?
Yes. The panel should be scoped to the host organism, recombinant construct, bank type, process stage, intended use and regulatory or quality requirements.
